Trials / Terminated

TerminatedNCT04086121

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

An Open Label Extension Study to Assess the Long Term Safety of Treatment With BI 655130 Administered Subcutaneously in Adult Patients With Moderate to Severe Atopic Dermatitis

Status: Terminated
Phase: Phase 2
Study type: Interventional
Enrollment: 14 (actual)

Sponsor: Boehringer Ingelheim · Industry
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032

Conditions

Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	Spesolimab	Solution for SC injection

Timeline

Start date: 2019-09-24
Primary completion: 2021-04-28
Completion: 2022-02-23
First posted: 2019-09-11
Last updated: 2025-02-24
Results posted: 2022-05-18

Locations

10 sites across 3 countries: United States, Canada, Japan

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04086121. Inclusion in this directory is not an endorsement.